Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.
about
Population pharmacokinetics of emtricitabine in HIV-1-infected adult patientsRandomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.Current pharmacotherapy for the treatment of chronic hepatitis B.Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor.New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.Review article: Nucleoside analogues for the treatment of chronic hepatitis B.HIV-1/hepatitis B coinfection.Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)Telbivudine: a novel nucleoside analog for chronic hepatitis B.Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.A review of oral antiretroviral therapy for the treatment of chronic hepatitis B.Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection modelCombinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005).Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection.In vitro interactions between apricitabine and other deoxycytidine analoguesNovel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents.BHIVA Guidelines: coinfection with HIV and chronic hepatitis B virus.
P2860
Q33622825-50D03617-2828-4657-B220-7D6F174705B0Q34648598-131CF303-093E-4D39-912F-E717717BBFC8Q35548194-1F3BE295-2873-4FD7-9820-36962F0A3933Q35609730-F98BC54E-193D-4F1B-94E7-667A7072CCE0Q35762280-351BAD28-8AFD-48DB-B690-2AF441ADD857Q35939695-AED5067F-4622-44B4-BA96-13007F0D8D17Q35987869-B20D5058-1C7E-4E1E-A899-1D4C453AA503Q36140666-6F7B73D8-6187-405B-BE65-BEDC63E3D874Q36243626-653F7D86-A0E5-4F15-9936-8D790F26261BQ36328961-5858F9CF-5FA8-443F-80EC-9E3CC04F3861Q36406923-47ED4E17-32DD-46E2-9386-BE4721E21FA0Q36409512-B7A52E9B-D64A-44F0-861D-6906BBDE76E7Q36706781-47F883CA-51DE-4304-BA61-B9CC739DC987Q37768591-E24AD15E-8406-4D08-89EA-FD27346F072DQ39755479-27FFB366-F61B-4BC0-9346-A780D76CCC6FQ40164099-2051C485-126A-4722-A43C-DC580779C249Q40312810-7BE08834-3383-4091-AD1F-1548F5C94F79Q40406133-39C0E076-0C2B-4E11-A894-5587B757413FQ40747185-66DBA371-E385-482E-9093-4D1B0C4A47A2Q40968070-72B9E7A3-0E32-4638-A071-2F97DE65F370Q42041046-9A27EE7C-C940-404F-BC63-CD51137822AFQ44517505-851F73EF-7FE0-43AB-A5EA-410AB7993EEDQ45711101-9FF97D04-9E28-45B1-A225-B00E588AB870
P2860
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Dose range study of pharmacoki ...... h hepatitis B virus infection.
@ast
Dose range study of pharmacoki ...... h hepatitis B virus infection.
@en
Dose range study of pharmacoki ...... h hepatitis B virus infection.
@nl
type
label
Dose range study of pharmacoki ...... h hepatitis B virus infection.
@ast
Dose range study of pharmacoki ...... h hepatitis B virus infection.
@en
Dose range study of pharmacoki ...... h hepatitis B virus infection.
@nl
prefLabel
Dose range study of pharmacoki ...... h hepatitis B virus infection.
@ast
Dose range study of pharmacoki ...... h hepatitis B virus infection.
@en
Dose range study of pharmacoki ...... h hepatitis B virus infection.
@nl
P2093
P2860
P1476
Dose range study of pharmacoki ...... th hepatitis B virus infection
@en
P2093
F Rousseau
H A Kessler
J Delehanty
N W Y Leung
P2860
P304
P356
10.1128/AAC.46.6.1734-1740.2002
P407
P50
P577
2002-06-01T00:00:00Z